EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis

Yi Zhou, Guofei Cui, Hongwei Xu, Joanne Chun, Doris Yang, Zheng Zhang, Lihui Yang, Jingxiao Wang, Meijuan Wan, Diego F Calvisi iD, Shumei Lin, Xin Chen iD und 1 weitere

Cell Death & Disease · 2023

DOI: 10.1038/s41419-023-05958-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Death & Disease, 2023. Verfasst von Yi Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a deadly malignancy with high genetic heterogeneity. TP53 mutation and c-MET activation are frequent events in human HCCs. Here, we discovered that the simultaneous mutations in TP53 and activation of c-MET occur in ~20% of human HCCs, and these patients show a poor prognosis. Importantly, we found that concomitant deletion of Trp53 and overexpression of c-MET (c-MET/sgp53) in the mouse liver led to HCC formation in vivo. Consistent with human HCCs, RNAseq showed that c-MET/sgp53 mouse HCCs were characterized by activated c-MET and Ras/MAPK cascades and increased tumor cell proliferation. Subsequently, a stably passaged cell line derived from a c-MET/sgp53 HCC and corresponding subcutaneous xenografts were generated. Also, in silico analysis suggested that the MEK inhibitor trametinib has a higher inhibition score in TP53 null human HCC cell lines, which was validated experimentally. We consistently found that trametinib effectively inhibited the growth of c-MET/sgp53 HCC cells and xenografts, supporting the possible usefulness of this drug for treating human HCCs with TP53 -null mutations. Altogether, our study demonstrates that loss of TP53 cooperates with c-MET to drive hepatocarcinogenesis in vivo. The c-MET/sgp53 mouse model and derived HCC cell lines represent novel and useful preclinical tools to study hepatocarcinogenesis in the TP53 null background.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor Suppressor Protein p53Proto-Oncogene Proteins c-metAnimalsHumansMiceCarcinogenesisCell Line, TumorMutation

Substanzen

TP53 protein, humanTumor Suppressor Protein p53MET protein, humanProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, San Francisco, CA, USA.
  • Liver Cancer Laboratory, University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Diego F Calvisi, Xin Chen, Haichuan Wang

Förderung

  • NIDDK NIH HHS
  • NCI NIH HHS
  • Foundation for the National Institutes of Health
  • National Natural Science Foundation of China
  • Sichuan Science and Technology Program

Zitieren

APA

Zhou, Y., Cui, G., Xu, H., Chun, J., Yang, D., Zhang, Z., Yang, L., Wang, J., Wan, M., Calvisi, D. F., Lin, S., Chen, X., & Wang, H. (2023). Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis. Cell Death & Disease. https://doi.org/10.1038/s41419-023-05958-y

Vancouver

Zhou Y, Cui G, Xu H, Chun J, Yang D, Zhang Z, et al. Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis. Cell Death & Disease. 2023. doi:10.1038/s41419-023-05958-y

BibTeX
@article{Zhou2023,
  author = {Zhou, Yi and Cui, Guofei and Xu, Hongwei and Chun, Joanne and Yang, Doris and Zhang, Zheng and Yang, Lihui and Wang, Jingxiao and Wan, Meijuan and Calvisi, Diego F and Lin, Shumei and Chen, Xin and Wang, Haichuan},
  title = {Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis},
  journal = {Cell Death & Disease},
  year = {2023},
  doi = {10.1038/s41419-023-05958-y}
}
Kostenlos starten →